Obdulio Piloto

Obdulio Piloto received his undergraduate education at Cornell University, majoring in Microbiology. After graduating at the top of his class in 2000, Obdulio went on to further his training at the Johns Hopkins University where he did his graduate thesis research on cancer immunotherapy in the lab of Donald Small MD PhD. Obdulio graduated with his PhD in 2006, then hopped over to the west coast where he pursued post-doctoral research at Stanford University. He further nurtured his interest in clinically relevant research, focusing on small molecule and peptide inhibitors for leukemia. Obdulio’s next stop was Exelixis where as a Research Scientist he managed a team focused on small molecule inhibitors for various diseases. In 2010, Conversant Biologics hired Obdulio as its Chief Scientific Officer. Obdulio transformed Conversant from being a provider of biospecimens into an innovative partner to biotech and pharma companies offering value-added human primary samples and services. Obdulio was part of the executive team responsible for Conversant being ranked #2 by The Scientist in 2011 for ‘Best Places to Work’. In 2011, Obdulio left Conversant to co-found Entopsis.

Ian Cheong

Ian Cheong started as a lawyer in 1999. In the course of his work in a law firm, Ian had the opportunity to interact with scientifically-trained clients. After deciding that science was too much fun to be left to the scientists, he left his job at the law firm to train as a scientist. Ian enrolled as a science undergraduate, but a year and a half into his studies, he was offered a scholarship to attend graduate school at the John Hopkins University. Focusing on cancer therapeutics, he completed his thesis (2007) and post-doctoral research (2010) under Bert Vogelstein MD. During this time, Ian also received an award at the Collegiate Inventors Competition. Ian is currently involved in Entopsis in an advisory position and handles computational aspects of Entopsis’s technology. Ian is also a Principal Investigator at the Temasek Life Sciences Laboratory in Singapore where he conducts research pertaining to drug delivery.

George Huang

George Huang is a precocious and multi-faceted individual with successful track records in finance, healthcare, research and real estate. George started out in graduate school doing his thesis research in the lab of Chemistry Nobel Laureate Professor Peter Agre MD at the Johns Hopkins University. After graduating with his PhD in 2006, George became an Editor with Stansberry Research and wrote an investment research newsletter which had a loyal following among biotech-savvy Wall Street institutional clients. Not surprisingly, he was headhunted to be a Senior Analyst at Sabretooth Capital, a billion-dollar ‘Tiger Cub’-pedigree hedge fund in New York City. His other success in New York was as Senior Vice President of Business Development with Retrophin Inc. (RTRX – listed on NASD), a biotechnology company, where he evaluated acquisitions and helped bring the company public. In 2014, George left New York to co-found Bridge Tower, a real estate investment fund. In the same year, George joined the Entopsis core team as its CFO.

Tingjun Lei